Novo Nordisk A/S (NYSE:NVO)
$ 134.66 1.74 (1.31%) Market Cap: 599.89 Bil Enterprise Value: 602.45 Bil PE Ratio: 46.60 PB Ratio: 41.56 GF Score: 92/100

Novo Nordisk A/S at American Heart Association Conference Transcript

Nov 11, 2023 / 11:00PM GMT
Daniel Bohsen;S;CVP;Head of IR
Novo Nordisk A

/-&

Good evening, and a warm welcome to Novo Nordisk Investor Event in connection with the American Heart Association Annual Conference here in Philadelphia. My name is Daniel, and I'm heading up Investor Relations at Novo Nordisk. Also a warm welcome to those of you following the webcast online.

I have to say that even though we're going to talk about SELECT and the results have been published today, that we could still end up talking about forward-looking statements. So please look at the disclaimers as always. This is the agenda we are going to discuss SELECT in detail, and we'll have two presenters, and I'll get back to them.

Just before we dive into SELECT, this is our strategic aspirations. This is the way we report on our strategy progress in Novo Nordisk. We recently reported our results for the first 9 months of this year, and we continue to make progress on our different aspirations. Notice we now treat around 40 million people within diabetes. Majority of those being on insulin,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot